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40 The Journal of Thoracic and Cardioackground: The left atrial appendage is a frequent source of thromboemboli in
atients with atrial fibrillation. Exclusion of the left atrial appendage may reduce the
isk of stroke in patients with atrial fibrillation. The atrial exclusion device, previ-
usly developed to perform left atrial appendage exclusion on a beating heart, was
odified to accommodate different anatomic patterns of the human left atrial
ppendage and to ensure uniform pressure and occlusion. The purpose of this study
as to evaluate this second-generation atrial exclusion device during a midterm
eriod in a canine model.
ethods: Ten mongrel dogs (mean weight 28.9  4.6 kg) were used in this study.
he atrial exclusion device, constructed from two parallel and rigid titanium tubes
nd two nitinol springs with a knit-braided polyester fabric, was implanted at the
ase of the left atrial appendage through a left thoracotomy on a beating heart using
specially designed delivery tool. Dogs were evaluated at 30 days (n  4) and 90
ays (n  6) by epicardial echocardiography, left atrial and coronary angiography,
ross pathology, and histologic inspection.
esults: Device implantation was performed without complications in all dogs.
omplete left atrial appendage exclusion without device migration or hemodynamic
nstability was confirmed, and there was no damage to the left circumflex artery or
ulmonary artery. Macroscopic and microscopic assessments revealed favorable
iocompatibility during midterm follow-up.
onclusion: The atrial exclusion device enabled rapid, reliable, and safe exclusion
f the left atrial appendage. Clinical application may provide a new therapeutic
ption for reducing the risk of stroke in patients with atrial fibrillation.
 
he left atrial appendage (LAA) is a frequent source of thromboemb
patients with atrial fibrillation (AF), contributing to a 5-fold increase of
stroke risk in patients with AF.1 In previous reports, approximately 60% a
1% of left atrial (LA) thrombi occurred in the LAA in rheumatic AF and
onrheumatic AF, respectively.2,3 However, considering that nonrheumatic AF 
ow more common than rheumatic AF and that compliance with guidelines for
nticoagulation therapy for AF is suboptimal, there is interest in investigating the
ole of LAA exclusion as a therapeutic alternative for reducing stroke risk in AF
atients.4,5 Several novel techniques for LAA exclusion using thoracoscopic 
ercutaneous approaches have been reported.6-10
A novel device, the atrial exclusion device (AED), has been developed for
picardial LAA exclusion on a beating heart. In a previous study,11 the first-
eneration AED (first AED) was evaluated, and the validity of the AED concept was
onfirmed. Subsequently, a second-generation AED was developed with design
odifications optimized to ensure uniform compression and occlusion of the ana-
vascular Surgery ● August 2006
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ETomically variable human LAA. The purpose of this pre-
linical study was to determine the safety and effectiveness
f the second-generation AED (second AED).
aterial and Methods
esign of the Second AED
he second AED is designed as a self-compensating force distri-
ution clamp, in contrast to the bi-staple clamp design of the first
ED.11 The skeleton of the AED is composed of two par
urved, rigid titanium tubes and two nitinol springs with a 90°
ngle at both ends of the titanium tubes (Figure 1, A). The rigid
itanium tubes are covered with both a urethane elastomer and a
nit-braided polyester sheath (Figure 1, B). These refinements provid
he following characteristics: (1) suitable contour to match the LAA
natomy; (2) evenly distributed clamping pressure; (3) rapid pro-
otion of tissue ingrowth to securely anchor the device and
revent damage to surrounding structures, such as the left circum-
ex artery (LCX) and the pulmonary artery (PA); and (4) circular
ontour of both ends of the device to minimize contact with the
A. There are two different sizes of the second AED (35 mm and
0 mm in length) to accommodate variability in the patient’s LAA
rifice size. It is envisioned that intermediate sizes would be made
vailable to allow optimal clip to anatomy relationship.
Figure 1, C shows a specially designed delivery tool with l
rms that facilitates device application. The tool has two config-
rations: open, in which the distance between the members of the
ttached AED is the greatest (Figure 1, B ) and closed, in whic
he AED is manipulated into a closed position. With the tool in the
pen position, the AED is placed over the LAA and positioned at
ts base by closing the delivery tool. If the AED is deployed and
he position on the LAA is judged to be suboptimal, the device can
e repositioned and reapplied by reattaching the delivery tool to
he implanted AED.
nimal Study
total of 10 mongrel dogs, weighing 28.9  4.6 kg, were used in
his study. This study was approved by the Cleveland Clinic’s
nstitutional Animal Care and Use Committee, and all animals
eceived humane care in compliance with the “Guide for the Care
nd Use of Laboratory Animals” prepared by the Institute of
aboratory Animal Resources, National Research Council, and
ublished by the National Academy Press, revised 1996.
Implant and explant studies. The surgical procedures in the
Abbreviations and Acronyms
AED  atrial exclusion device
AF  atrial fibrillation
2DEE 2-dimensional epicardial echocardiography
EDV  end-diastolic volume
ESV  end-systolic volume
LA  left atrial
LAA  left atrial appendage
LCX  left circumflex artery
PA  pulmonary arterymplant and explant studies were similar to the previously reported t
The Journal of Thoraciceries of animal study with the exception of the device implant
echnique.11 In brief, the dogs were placed in the right lateral po
ith electrocardiogram leads attached under general anesthesia. The
eft carotid artery was cannulated for continuous monitoring of sys-
emic arterial pressure. After a thoracotomy in the left fourth inter-
ostal space, the pericardium was opened to expose the LAA. A
4-gauge angiocatheter was inserted into the left pulmonary vein
o monitor the LA pressure and perform LA angiography. A
5-mm AED was chosen for implantation in 8 animals because of
he LAA orifice size in those dogs. In the remaining 2 dogs, an
versized device, a 50-mm AED, was intentionally used to assess
he impact of implanting an oversized device. The AED was
laced over the end of the LAA and aligned with the base of the
AA using the delivery tool (Figure 2, A). Once in the desir
osition, the AED was released by gently closing the delivery tool.
In addition to hemodynamic parameters, 2-dimensional epicar-
ial echocardiography (2DEE), Doppler echocardiography, and
A angiography in the 60° left anterior oblique and 30° right
nterior oblique planes were performed. The LA area was mea-
ured by planimetry in the apical 4-chamber view. The LA volume
as also assessed by a biplane area-length method from the apical
- and 2-chamber views. The left ventricular end-diastolic (EDV)
nd end-systolic volumes (ESV) were measured by the single-plane
impson rule. Left ventricular ejection fraction was calculated by the
quation 100  (EDV – ESV)/EDV. The left ventricular stroke
olume was calculated as the difference of EDV and ESV. Data
cquisition was performed as described in our previous report.11 The
hest was closed with a chest tube in place. Eight dogs with a 35-mm
evice were followed up for 30 days (n  2) and 90 days (n  6).
wo dogs with a 50-mm device were followed up for 30 days.
On the day of the explant study, the pericardium was reopened
o expose the implanted AED. Hemodynamic assessment, LA
ngiography, 2DEE, and Doppler echocardiography were per-
ormed in the same manner as at the implant study. Furthermore,
n all 90-day dogs, left coronary angiography was conducted to
valuate LCX blood flow in the left anterior oblique 60° and right
nterior oblique 30° planes.
To evaluate electrical isolation between the LAA (distal to the
ED) and LA body (proximal to the AED), we applied electrical
timulation to two different locations at a pacing rate greater than
he native rate during sinus rhythm in three 30-day and four 90-day
ogs. Standard epicardial pacing wires were placed on the LA
ody and LAA remnant. LA body pacing was performed in asyn-
hronous mode to confirm that the heart could be paced. Electrical
timulation at a maximum current of 20 mA was applied to the
AA in the same manner as during LA body pacing. When the
AA pacing was not accomplished at 20 mA, it was determined
hat the distal LAA was completely electrically isolated. However,
hen LAA pacing was accomplished at 20 mA, the pacing thresh-
ld of the LAA was measured with a stepwise decrease of the
acing current. If the LA body pacing could be established at less
han half of the LAA pacing threshold, it was concluded that the
AA was partially electrically isolated.
Gross necropsy and histologic evaluation. After full hepa-
inization, the dogs were humanely killed by rapid intravenous in-
ection of sodium pentobarbital and potassium chloride. The heart was
xamined to confirm LAA exclusion and to determine tissue response
o the polyester fabrics for gross biocompatibility evaluation.
and Cardiovascular Surgery ● Volume 132, Number 2 341
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ETTissue specimens of the cross section of the entire LAA,
ncluding the polyester fabric and a small part of the LA body
adjacent to the orifice of the LAA), were excised and evaluated.
he tissues were fixed in 10% formalin for 48 hours and embedded
n paraffin. Sections were cut from each block at 4 m and
ollected onto glass slides. All sections were then dried for 60
inutes at 60°C and stained with hematoxylin and eosin.
ata Analysis
ll values were expressed as mean  standard deviation. Repeated-
easures analysis of variance was used to assess the differences
etween data at baseline, pre-implantation, and follow-up.42 The Journal of Thoracic and Cardiovascular Surgery ● Auguesults
mplantation
he AED was implanted on a beating heart in all dogs
ithout any complications or hemodynamic instability. The
ime required for initial AED application was approximately
5 seconds once the LAA was exposed. Only 1 dog required
eapplication. The AED was precisely placed at the base of
he LAA without causing acute damage to surrounding
tructures, such as the LA body, LCX, and PA (Figure B).
n the 2 dogs that received an oversized 50-mm AED, no
cute compression of the PA was found even though the
Figure 1. The second-genera-
tion atrial exclusion device
(AED) and the specially de-
signed delivery tool. A, The
skeleton of the AED, in the
closed position, is composed
of two titanium rigid tubes and
two nitinol springs with a 90°
angle at each end of the tubes.
B, The AED with a polyester
fabric in the open position.
The titanium tubes are cov-
ered with both a urethane
elastomer and a knit-braided
polyester sheath. C, The deliv-
ery tool has long arms that al-
low device application to a
distant anatomic structure.
Figure 2. Representative intra-
operative views at implantation.
A, The AED can be precisely po-
sitioned and then implanted us-
ing the delivery tool. B, The AED
was implanted at the base of the
LAA. The cranial end of the de-
vice was located underneath the
main PA. *, LAA, Left atrial ap-
pendage; AED, second-generation
atrial exclusion device; PA, pul-
monary artery; LAD, left anterior
descending artery; OM, obtuse
marginal artery; LV, left ventri-
cle.st 2006
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ETdge of the device was positioned in direct contact with the
ain PA. Post-implant 2DEE, Doppler echocardiography,
nd LA angiography revealed no communication between
he LAA and LA body and absence of blood flow in the
AA. All animals survived the procedure without device-
elated complications and had uneventful postoperative re-
overy periods.
xplantation
t explantation, the AED remained positioned at the base of
he LAA with no evidence of migration. Structures adjacent
o the device, such as the LA body, LCX, and PA, were
ntact without erosion. The LAA in the 30-day dogs was
oderately atrophied. All 6 of the 90-day dogs had dense
dhesions surrounding the AED with marked atrophy of the
AA. With respect to the 2 dogs with a 50-mm device, there
ere no adverse effects on the main PA; we observed
either PA erosion nor compression. Before explantation,
oppler echocardiography and LA angiography confirmed
ack of communication between the LAA and LA in all
ogs. In addition, coronary angiography in all 90-day dogs
emonstrated normal LCX anatomy with no apparent ob-
truction to blood flow (Figure 3, A and B). Hemodynamic
ata are summarized in Table 1. There were no stati
hanges in hemodynamics throughout the studies. With
espect to the LA size, no difference in the LA area (mea-
ured in all animals) or LA volume (measured in 6 animals
ue to unsatisfactory image resolution) was found, which
ay indicate no device migration. In addition, there were no
ignificant differences in the 2DEE parameters such as
DV, ESV, stroke volume, and ejection fraction. In the
hree 30-day and four 90-day dogs that were subjected to
acing assessment, either total (n  4) or partial (n  3)
lectrical isolation of the LAA remnant was confirmed. m
The Journal of Thoracicl
ross and Histologic Examinations
ll dogs had tissue ingrowth that completely covered the
ntire AED. Examination of the inside of the LA revealed a
mooth endocardial surface at the origin of the LAA with no
ul-de-sac formation and no evidence of thrombus associ-
ted with the AED (Figure 4, A). In the cross section of 
cclusion site at 30 and 90 days, the LAA walls underneath
he AED were firmly adherent to each other. As illustrated
n Figure 4, B (small arrows), the occlusion site was cle
nd smooth. The internal cavity of the excluded and atro-
hied LAA was occupied by a well-organized thrombus or
ense connective tissue, resulting in elimination of the LAA
Figure 3. Representative angio-
graphic findings of the LCX at ex-
plantation. A and B, No adverse
effects of the implanted AED on
the LCX (dotted arrows) were
found in LAO 60° or RAO 30°
planes. AED, Second-generation
atrial exclusion device; LCX, left
circumflex artery; LAO, left ante-
rior oblique; RAO, right anterior
oblique.
ABLE 1. Case information
Baseline
Post-LAA
exclusion Follow-up
emodynamics
Heart rate (beats/min) 128 16 128 14 128 15
SBP (mm Hg) 124 20 126 16 116 10
DBP (mm Hg) 82 15 79 14 79 16
MBP (mm Hg) 102 19 105 19 91 11
Mean LAP (mm Hg) 6.9 3.4 7.2 3.3 6.7  2.2
DEE
Left atrial area (cm2) 11.0 3.1 10.6 2.5 9.6 1.8
Left atrial volume
(cm3)*
28.7 3.8 24.8 4.2 24.2 5.0
EDV (mL) 60.5 19.4 58.7 20.7 59.8 18.9
ESV (mL) 25.9 9.6 26.1 12.4 25.3 12.6
SV (mL) 34.4 14.8 33.2 13.9 34.1 12.3
EF (%) 52.1 12.1 49.0 15.7 53.2 10.2
AA, Left atrial appendage; SBP, systolic blood pressure; DBP, diastolic
lood pressure; MBP, mean blood pressure; LAP, left atrial pressure; 2DEE,
-dimensional epicardial echocardiography; EDV, end-diastolic volume;
SV, end-systolic volume; SV, stroke volume; EF, ejection fraction. No
ignificant difference was found among each data point. *The measure-
ents of left atrial volume were possible in 6 animals.
and Cardiovascular Surgery ● Volume 132, Number 2 343
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ETumen. The great cardiac vein and LCX were intact without
ny thrombus formation (Figure 4, B, dotted arrows). In th
dogs with an oversized 50-mm AED, the intimal surface
here the cranial end of the device was located wa
pected, and no damage to the PA intima was observed.
Figure 4. Gross anatomic views of the internal surface
site at 90 days. A, The arrows indicate a smooth, clea
found. B, The occlusion line was fully covered with o
underneath both fabrics were very thin and were firmly
its lumen was occupied with white connective tissu
sections of the great cardiac vein and left circumflex a
both vessels. LAA, Left atrial appendage; LA, left atriu44 The Journal of Thoracic and Cardiovascular Surgery ● Augu-
Hematoxylin-and-eosin–stained vertical sections of the
ntire LAA including the distal LAA, LAA walls at the
cclusion site, the polyester fabric with tissue ingrowth, and
A body were inspected. The distal LAA tissues taken from
oderately atrophied LAA (30-day dogs) showed myocar-
he LAA orifice and the cross section of the occlusion
d linear occlusion site. No cul-de-sac formation was
yer of tissue ingrowth (small arrows). The LAA walls
rent to each other. The distal LAA was atrophied, and
e large and small dotted arrows indicate the cross
, respectively. There was no intraluminal thrombus in
, left ventricle.
Figure 5. Histologic findings of
the cross section of the occlusion
site at 90 days. A, The endocar-
dial surface of the occlusion site
was covered with endothelium-
like cells without producing ir-
regularity on the endocardial
surface (magnification  20). B,
The fibrous connective tissue
with fibroblast infiltration was
found between both fabrics and
around the fabrics (magnifica-
tion  200). C, A neoendothelial
layer and underlying layers of
connective tissue expanding on
the endocardial surface of the
occlusion site were found (mag-
nification  200). *, Left atrial
musculature; LA, left atrium; LAA,
left atrial appendage; LV, left
ventricle; LCX, left circumflex
artery.of t
r, an
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ETium with fatty infiltration, whereas the myocardial tissues
rom markedly atrophied LAA (90-day dogs) were replaced
y fibrous tissue. Figure 5 shows the histologic finding
he cross section of Figure 4, B. There was one layer 
ndothelium-like cells and underlying layers of connective
issue that expanded on the endocardial surface of the oc-
lusion site (Figure 5, A and C). The polyester fabric w
overed by fibrous connective tissue with fibroblast infiltra-
ion in 30- and 90-day dogs (Figure 5, B). The LAA wal
nderneath the AED were replaced by fibrous tissue. The
ross section of PA tissue taken from the site where the
ranial end of the 50-mm device contacted the PA adventitia
evealed no histologic abnormalities.
iscussion
he second AED completely excluded the LAA from the
ystemic circulation and did not migrate or cause damage to
djacent cardiac structures at 30- and 90-day follow-up. No
hanges in the parameters related to LV volume, such as
DV, ESV, stroke volume, and ejection fraction, were
ound at follow-up. Macroscopic and microscopic assess-
ents also revealed favorable biocompatibility. In addition,
he AED provided partial or total electrical isolation of the
AA in 7 of 7 cases.
AF is epidemiologically the most common cardiac ar-
hythmia, and its prevalence increases in both genders after
0 years and rises rapidly after 65 years.1,12 Although recent
andomized trials have demonstrated that anticoagulation
an greatly reduce the stroke rate in patients with AF13,14
any physicians remain reluctant to prescribe anticoag-
lant therapy for elderly AF patients because of an in-
reased risk of anticoagulant-related complications with
ge, the difficulty of warfarin management, and personal
reference.4,5,15
A potential alternative or adjunctive approach to stroke
revention in AF patients is surgical exclusion of the LAA.
arious techniques for LAA exclusion either from the ex-
erior of the heart or from inside the LA during cardiac
urgery have been introduced; however, several potential
isadvantages such as bleeding and late recanalization ex-
st.16-19 Although an epicardial approach to LAA exclus
as the potential advantages of simplicity (no transseptal
uncture) and low procedural risk of embolism (no left heart
ndocardial catheters), there is currently no instrumentation
vailable to facilitate rapid, reliable, and safe epicardial
xclusion of the LAA.
This novel device, the AED, has application for epicar-
ial LAA exclusion. The benefit of this type of occlusion
evice is the simplicity of device application on a beating
eart. In our previous preclinical study, we confirmed LAA
xclusion in a canine model, validating the AED conce11
owever, we had concluded that refinement of device de-ign would provide improved clinical application. Because A
The Journal of Thoracicf
here are many anatomic patterns of the LAA (ie, shape,
ize, and thickness) in humans, a distributed clamping pres-
ure distribution across the width of the device was required
o that the device adapts to accommodate the variability of
AA anatomy. Therefore, a design modification of the first
ED was made without eliminating the advantages of the
ED (namely, the easy device application and reapplication
nd favorable biocompatibility) resulting in the develop-
ent of a self-compensating force distribution concept, the
econd AED. In addition, since a self-compensating force
istribution requires physical force to be opened for appli-
ation, a specially designed delivery tool was also devel-
ped to precisely position and apply the second AED on the
AA. This delivery tool permits easy device repositioning
nd reapplication if initial placement is unsatisfactory.
Thrombus formation on a cul-de-sac or occlusion line
ormed by the device application at the origin of the LAA is
onsidered one of the most potential and important compli-
ations in the chronic phase. In this study, the AED was
asily and precisely placed at the base of the LAA, and the
esulting occlusion line was smooth and linear without any
ndocardial furrow or cul-de-sac formation (Figure 5, A ).
n addition, histologic examination revealed that the en-
ocardial surface of the occlusion site was covered with
ndothelium-like cells without producing irregularity on the
ndocardial surface. These findings suggest that the throm-
us formation on the occlusion line may be unlikely to
ccur even in patients with AF. LA and coronary angiog-
aphy and echocardiography confirmed complete exclusion
f the LAA at 30 and 90 days without device migration or
amage to the PA, LCX, or other adjacent cardiac struc-
ures. As illustrated in Figure 2, B the cranial end of t
econd AED was located underneath the main PA without
ompressing the PA; this lack of compression is attributed
o the unique configuration of the 90° nitinol springs at
ither end of the titanium tubes. The design and physical
haracteristics of the AED and tissue ingrowth around the
olyester covering prevented device migration and damage
o adjacent cardiac structures.
Compared with epicardial stapling devices,18,19 the AED
ffers two advantages: (1) easy reapplication and (2) elim-
nation of the risk of bleeding that may occur along or
eneath the staple line. Other occlusion devices currently
vailable, such as a surgical stapler or clip applier, perma-
ently deform the occlusion apparatus, thereby delivering a
ermanent implant. The promotion of distal LAA atrophy
y the AED may eliminate the possibility of late recanali-
ation of the LAA lumen, one of the potential problems of
oncutting stapling devices.16,17
Although not assessed specifically in this study, the
pecially designed delivery tool may enable a minimally
nvasive thoracoscopic approach for LAA exclusion in lone
F patients, providing a possible therapy for stroke preven-
and Cardiovascular Surgery ● Volume 132, Number 2 345
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ETion. In addition, several reports have indicated that the
AA may be one source of thrombus in patients in sinus
hythm with congestive heart failure.20,21 The AED and i
elivery tool may be beneficial for these high-risk patients
n sinus rhythm to prevent embolic events resulting from
AA thrombi. However, it is likely that in patients with
AA thrombi that extend to the orifice of the LAA, epicar-
ial approaches should be avoided.
There are limitations to this preclinical study. The study
eries was small (n  10), and the follow-up duration was
nly a maximum of 90 days. In addition, the application of
normal canine model in this study provided us with
dealized implant situations (ie, narrow LAA base, absence
f increased LA wall tension or pressure resulting from LA
nlargement, absence of LAA fragility caused by advanced
ge, malnutrition, or other etiology). It is possible that there
ay be device failures and/or complications of deployment
ith longer follow-up or with application in patients who do
ot have tissues as resilient as those of a healthy dog.
urthermore, the possibility of LA thrombus formation after
ED application in an AF setting cannot be excluded in this
tudy. Although a very smooth and linear endocardial sur-
ace of the occlusion line was found with no cul-de-sac
ormation in this study, this finding does not alone indicate
hat the AED can completely eliminate the risk of thrombus
ormation on the occlusion line in the long-term phase.
herefore, future evaluations using an AF animal model
ay be required to confirm the long-term stability, durabil-
ty, and biocompatibility of the device as well as the exis-
ence of thrombus formation.
Although LAA exclusion may cause potential adverse
ffects because of reduced production of serum natriuretic
eptide,22,23 we did not analyze biochemistry levels such
erum natriuretic peptide, troponin, and creatine kinase. In
his series, however, no clinical signs of heart failure (gen-
ral fatigue or significant changes in the weights and heart
ates of dogs) were observed. In preparation for clinical
ED application, further study will also be required to
nderstand the neurohumoral effects of LAA exclusion.
onclusions
he second-generation AED provides a potential new ther-
peutic option for stroke prevention in patients with AF.
he device has been redesigned to enhance its performance,
nd preclinical safety and effectiveness studies are encour-
ging. Further animal studies in an AF model are warranted
o better simulate clinical conditions.
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